Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 8/20 | 0.35 |
| ▸ | GPBAR1 | Q8TDU6 | 6/20 | 0.35 |
| ▸ | CYSLTR2 | Q9NS75 | 4/20 | 0.35 |
| ▸ | DHFR | P00374 | 1/20 | 0.34 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6091137 | 0.86 | CYSLTR1 (0.45) | CYSLTR1GPBAR1CYSLTR2PDE10A | |
| SCHEMBL6089349 | 0.85 | CYSLTR1 (0.44) | CYSLTR1GPBAR1CYSLTR2 | |
| SCHEMBL6090077 | 0.84 | CYSLTR1 (0.42) | CYSLTR1GPBAR1CYSLTR2FFAR1 | |
| SCHEMBL6087968 | 0.82 | CYSLTR1 (0.56) | CYSLTR1GPBAR1CYSLTR2PDE10A | |
| SCHEMBL7469798 | 0.82 | CYSLTR1 (0.40) | CYSLTR1GPBAR1CYSLTR2PDE10A | |
| SCHEMBL7469808 | 0.82 | CYSLTR1 (0.40) | CYSLTR1GPBAR1CYSLTR2PDE10A | |
| SCHEMBL6087715 | 0.80 | CYSLTR1 (0.40) | CYSLTR1GPBAR1CYSLTR2PDE10A | |
| SCHEMBL6089788 | 0.80 | CYSLTR1 (0.43) | CYSLTR1GPBAR1CYSLTR2 | |
| SCHEMBL6089679 | 0.79 | GPBAR1 (0.43) | CYSLTR1GPBAR1CYSLTR2PDE10A | |
| SCHEMBL6089925 | 0.77 | ABCB1 (0.42) | FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7005440-B1 | Therapeutic uses of tri-aryl acid derivatives | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2006-02-28 | — | — | US | disclosed |